| Literature DB >> 25844138 |
Sang Eun Lee1, Rak Min Choi2, Rim Kee2, Kang Hun Lee1, Sangyoon Jeon1, Jae-Wook Jung1, Woo-Jin Kim3, Jin Sun Yoon2.
Abstract
Spinal cord stimulation (SCS) in trials involving external stimulation are easily conducted under local anesthesia. However, implantation of a permanent SCS system is painful, and can be intolerable in some patients. Epidural anesthesia can be used to perform the SCS implantation without discomfort if the patient can localize the area of paresthesia. However, little is known about epidural anesthesia for SCS. This paper reports 23 cases of permanent SCS with a cylindrical type lead implanted under the epidural anesthesia. Epidural anesthesia was sufficient in 22 patients without discomfort and significant complications. The remaining patient experienced incomplete epidural anesthesia and required additional analgesics to blunt the pain. All the leads were placed consistent with the patient's report of paresthesia area under epidural anesthesia. Thus, epidural anesthesia is an effective and safe method for the optimal placement of SCS to minimize the discomfort for patients without impairing patients' response to the intraoperative stimulation test.Entities:
Keywords: Epidural anesthesia; Spinal cord stimulation
Year: 2015 PMID: 25844138 PMCID: PMC4384407 DOI: 10.4097/kjae.2015.68.2.179
Source DB: PubMed Journal: Korean J Anesthesiol ISSN: 2005-6419
Characteristics of Patients and Permanent SCS Implantation
| Characteristics of Patients (n) | |
|---|---|
| Sex (M/F) | 21/2 |
| Age (yr) | 62.7 ± 14.8 |
| Height (cm) | 164.7 ± 7.3 |
| Weight (kg) | 65.4 ± 12.1 |
| Interval between trial and permanent SCS (days) | 15.2 ± 6.7 |
| Diagnosis (%) | |
| Complex regional pain syndrome I | 10 (43.5) |
| Complex regional pain syndrome II | 2 (8.7) |
| Failed back surgery syndrome | 8 (34.8) |
| Multiple sclerosis | 1 (4.3) |
| Atherosclerosis obliterans | 2 (8.7) |
| Number of permanent SCS leads (%) | |
| 1 | 14 (60.9) |
| 2 | 9 (39.1) |
| Duration of permanent SCS (min) | 126.5 ± 41.4 |
Summary of Patient Charateristics and Permanent SCS
| Patient NO. | Sex/Age | Height | Weight | Diagnosis | Pain location | Local anesthetics | Block site | Sensory levels of blockade | The number of lead | Lead Placement | Adverse events | PreSCS VAS | PostSCS VAS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/73 | 161.6 | 56.6 | FBSS | Lower back + inferior left limb | 0.75% ropivacaine 13 ml | L2-3 | T6 | 2 | T8-T10 | H | 8 | 4 |
| 2 | F/84 | 146.4 | 52.6 | CRPS | Inferior right limb | 2% lidocaine 10 ml | L3-4 | T6 | 1 | T7-T10 | 9 | 4 | |
| 3 | M/70 | 160.5 | 70.8 | CRPS | Bilateral inferior limbs | 2% lidocaine 15 ml | L3-4 | Unknown | 2 | T11-L1 | H+B | 8 | 4 |
| 4 | M/67 | 163.5 | 64 | CRPS | Inferior right limb | 2% lodicaine 15 ml + 0.75% ropivacaine 15 ml | L4-5 | T4 | 1 | T11-T12 | H+B | 8 | 3 |
| 5 | M/63 | 169.7 | 76.4 | CRPS | Inferior right limb | 2% lidocaine 10 ml | L3-4 | Unknown | 2 | T10-T12 | P | 10 | 5 |
| 6 | M/57 | 178 | 88.7 | CRPS | Inferior right limb | 2% lodicaine 9 ml + 0.75% ropivacaine 9 ml | L3-4 | T6 | 1 | T10-T11 | H+B | 9 | 4 |
| 7 | M/67 | 165 | 58 | Multiple Sclerosis | Lower back + bilateral inferior limbs | 2% lodicaine 7.5 ml + 0.75% ropivacaine 7.5 ml | L3-4 | Unknown | 2 | T9-T11 | B | 9 | 4 |
| 8 | M/80 | 169 | 63.4 | CRPS | Inferior right limb | 2% lodicaine 8 ml + 0.75% ropivacaine 8 ml | L4-5 | T8 | 1 | T12-L1 | H+B | 9 | 3 |
| 9 | M/54 | 168 | 83 | CRPS | Inferior right limb | 2% lodicaine 8 ml + 0.75% ropivacaine 8 ml | L3-4 | T6 | 1 | T12-L1 | 9 | 3 | |
| 10 | M/67 | 163 | 78 | CRPS | Inferior right limb | 2% lodicaine 5 ml + 0.75% ropivacaine 5 ml | L4-5 | Unknown | 1 | T11-L1 | H+B | 10 | 4 |
| 11 | M/86 | 169.7 | 68.8 | CRPS | Bilateral inferior limbs | 2% lodicaine 7.5 ml + 0.75% ropivacaine 7.5 ml | L3-4 | T10 | 1 | T10-T11 | 9 | 3 | |
| 12 | F/54 | 148 | 68.3 | CRPS | Inferior right limb | 2% lodicaine 7.5 ml + 0.75% ropivacaine 7.5 ml | L3-4 | T8 | 1 | T10-T12 | H+B | 9 | 4 |
| 13 | M/69 | 165 | 51.7 | ASO, right leg | Inferior right limb | 2% lodicaine 10 ml + 0.75% ropivacaine 7.5 ml | L3-4 | T6 | 1 | T11-T12 | 8 | 3 | |
| 14 | M/38 | 169.2 | 58 | FBSS | Lower back + bilateral inferior limbs | 2% lodicaine 10 ml + 0.75% ropivacaine 10 ml | L2-3 | T8 | 1 | T10-T12 | 8 | 5 | |
| 15 | M/23 | 168 | 55 | CRPS | Inferior right limb | 2% lodicaine 8 ml + 0.75% ropivacaine 8 ml | L4-5 | T8 | 1 | T11-T12 | 9 | 4 | |
| 16 | M/38 | 165 | 70 | FBSS | Lower back + inferior right limb | 2% lodicaine 10 ml + 0.75% ropivacaine 10 ml | L2-3 | T6 | 1 | T9-T10 | 9 | 3 | |
| 17 | M/65 | 156.9 | 42.5 | FBSS | Bilateral inferior limbs | 2% lodicaine 7.5 ml + 0.75% ropivacaine 7.5 ml | L2-3 | T8 | 2 | T9-T11 | 9 | 4 | |
| 18 | M/55 | 159 | 68 | FBSS | Lower back + bilateral inferior limbs | 2% lodicaine 5 ml + 0.75% ropivacaine 10 ml | L2-3 | T6 | 2 | T8-T11 | N | 8 | 3 |
| 19 | M/64 | 169.7 | 70.3 | FBSS | Lower back + bilateral inferior limbs | 2% lodicaine 10 ml + 0.75% ropivacaine 10 ml | L2-3 | Unknown | 2 | T9-T11 | 8 | 3 | |
| 20 | M/69 | 170 | 67 | FBSS | Lower back + bilateral inferior limbs | 2% lodicaine 5 ml + 0.75% ropivacaine 10 ml | L2-3 | T6 | 2 | T11-T12 | H | 8 | 3 |
| 21 | M/74 | 168 | 48.2 | ASO, right leg | Inferior right limb | 2% lodicaine 5 ml + 0.75% ropivacaine 10 ml | L3-4 | T4 | 1 | T10-T11 | H | 8 | 3 |
| 22 | M/58 | 173.1 | 87 | FBSS | Lower back + inferior right limb | 2% lodicaine 5 ml + 0.75% ropivacaine 10 ml | L2-3 | T6 | 2 | T10-T12 | H | 8 | 4 |
| 23 | M/68 | 162 | 59 | CRPS | Inferior right limb | 2% lodicaine 5 ml + 0.75% ropivacaine 10 ml | L3-4 | T8 | 1 | T10-T11 | 8 | 4 |
SCS: spinal cord stimulation, FBSS: failed back surgery syndrome, CRPS: complex regional pain syndrome, ASO: atherosclerosis, PreSCS: before SCS, PostSCS: after SCS, VAS: Visual analogue scale, H: hypotension, B: Bradycardia, P: pain, N: nausea.
Fig. 1The electric current variables (mA) at the trial (T0), permanent (T1) and postoperative stimulation 3 days after surgery (T2). There was a significant difference between T0 and T1, and T1 and T2. *P < 0.001 T0 vs. T1; †P < 0.001 T1 vs. T2.